Also in edition #109 of This Week in Biotech: Lilly paid $2.8B upfront for AtaiBeckley, its 11th acquisition of 2026 and its entry into psychedelics Celcuity won a differentiated breast cancer approval and the stock still fell almost 20% Four biotech IPO filings in two weeks, $400M for Chai Discovery, $315M for AdvanCell
Great quality product
Our results indicate that in hDAT cells, AA, under both oxidative and non-oxidative conditions, decreases significantly and to the same extent plasma membrane DAT (Figures 4a and b) as determined by biotinylation
The cooking is simple and balanced, and the menu changes often enough to keep repeat visits interesting
[DOI] [PubMed] [Google Scholar] 83.Scheen A.J., Charpentier G., Ostgren C.J., Hellqvist A., Gause-Nilsson I
not detected, Lycopersicon esculentum (leaf)707 nmol/g GSH